ECSP024345A - Proteina asociada con enfermedad - Google Patents

Proteina asociada con enfermedad

Info

Publication number
ECSP024345A
ECSP024345A EC2002004345A ECSP024345A ECSP024345A EC SP024345 A ECSP024345 A EC SP024345A EC 2002004345 A EC2002004345 A EC 2002004345A EC SP024345 A ECSP024345 A EC SP024345A EC SP024345 A ECSP024345 A EC SP024345A
Authority
EC
Ecuador
Prior art keywords
syndrome
disease
protein
aging
methods
Prior art date
Application number
EC2002004345A
Other languages
English (en)
Inventor
Thierry Leveillard
Jose Alain Sahel
Said Saddeck Mohand
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP024345A publication Critical patent/ECSP024345A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen métodos y composiciones para el diagnostico inicial, monitoreo y tratamiento de distrofia retinal , degeneración macular relacionada con el envejecimiento síndrome de Bardet-Biedel, síndrome de Bassenkoornzweig, mal de Best, coroidema, astrofia giratoria, amourosis congénita, síndrome de Refsun; mal de Stargardt o Síndrome de Usher. en particular, la invención se refiere a una proteína, definida con el término "RdcVf1", que se transcribe y expresa diferencialmente en pacientes que padecen de distrofias retinales y lo similar, tal como distria retinal y degeneración macular relacionada con el envejecimiento con no pacientes, anticuerpos que reconocen esta proteína, y los métodos para diagnosticar tales condiciones.
EC2002004345A 2001-04-06 2002-11-19 Proteina asociada con enfermedad ECSP024345A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0104712A FR2823221B1 (fr) 2001-04-06 2001-04-06 Sequences associees a la degenerescence retinienne et applications

Publications (1)

Publication Number Publication Date
ECSP024345A true ECSP024345A (es) 2004-06-28

Family

ID=8862037

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2002004345A ECSP024345A (es) 2001-04-06 2002-11-19 Proteina asociada con enfermedad

Country Status (22)

Country Link
US (6) US7795387B2 (es)
EP (1) EP1379657B1 (es)
JP (2) JP4370428B2 (es)
KR (1) KR100913258B1 (es)
CN (1) CN1529753B (es)
AU (1) AU2002312794B8 (es)
BR (1) BRPI0208870B8 (es)
CA (1) CA2443345C (es)
CZ (1) CZ305800B6 (es)
EC (1) ECSP024345A (es)
ES (1) ES2597835T3 (es)
FR (1) FR2823221B1 (es)
HU (1) HU226307B1 (es)
IL (3) IL158013A0 (es)
MX (1) MXPA03009114A (es)
NO (1) NO331277B1 (es)
NZ (1) NZ528376A (es)
PL (1) PL213658B1 (es)
RU (1) RU2384586C2 (es)
SK (1) SK288465B6 (es)
WO (1) WO2002081513A2 (es)
ZA (1) ZA200307403B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823221B1 (fr) 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
JP4559429B2 (ja) 2003-05-21 2010-10-06 ジェンザイム・コーポレーション 空キャプシドを実質的に含まない組換えａａｖビリオン調製物を生成するための方法
FR2870241B1 (fr) 2004-05-13 2015-02-27 Novartis Ag Facteur de viabilite des cones derive des batonnets ou rdcvf et applications
EP2027889A1 (en) * 2007-06-05 2009-02-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) New neuronal viability factor and use thereof
WO2009146183A1 (en) 2008-04-15 2009-12-03 Genzyme Corporation Methods to produce rod-derived cone viability factor (rdcvf)
WO2010029130A1 (en) * 2008-09-10 2010-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuronal viability factor and use thereof
EP2383286A1 (en) 2010-04-30 2011-11-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
KR102000141B1 (ko) * 2011-10-27 2019-07-15 웰스테이트 옵탈믹스 코퍼레이션 간상세포 유래 원추세포 생존능 인자를 인코딩하는 벡터
WO2013124477A1 (en) 2012-02-24 2013-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
US10004780B2 (en) 2012-10-17 2018-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD)
PL3027646T3 (pl) 2013-07-31 2019-03-29 Novartis Ag Nowe wektory selekcyjne i sposoby selekcji eukariotycznych komórek gospodarza
JP6684343B2 (ja) * 2015-05-21 2020-04-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ニューロン生存因子の相乗組み合わせ及びその使用
US10857240B2 (en) 2016-01-05 2020-12-08 The Trustees Of The University Of Pennsylvania Methods and compositions for treatment of ocular disorders and blinding diseases
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
WO2018071465A1 (en) * 2016-10-11 2018-04-19 Wellstat Ophthalmics Corporation Fusion protein between short form rod-derived cone viability factor and a hydrophilic peptide
US20230146121A1 (en) * 2019-12-09 2023-05-11 Chigenovo Co., Ltd. Use of cyp4v2 and rdcvf in the manufacture of medicament
CN111733174B (zh) * 2020-08-07 2021-02-09 北京大学第三医院（北京大学第三临床医学院） 一种分离的核酸分子及其用途
US20250276088A1 (en) * 2021-07-07 2025-09-04 Institut National de la Santé et de la Recherche Médicale Synergistic combination of rdcfv2 and rdcvf2l for the treatment of tauopathies
CN113774019B (zh) * 2021-08-11 2024-02-13 东南大学 一种脐带血间充质干细胞无血清培养基、培养方法及其应用
AU2024254882A1 (en) 2023-03-30 2025-10-16 Pharma Cinq, Llc VECTOR ENCODING ROD-DERIVED CONE VIABILITY FACTOR AND HUMAN IgK SIGNAL SEQUENCE

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4771036A (en) * 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
GB9701710D0 (en) * 1997-01-28 1997-03-19 Karobio Ab Mammalian protein
US6106825A (en) * 1997-05-07 2000-08-22 University Of Florida Entomopoxvirus-vertebrate gene delivery vector and method
FR2784030B1 (fr) 1998-10-02 2002-12-20 Inst Nat Sante Rech Med Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine
FR2784898A1 (fr) 1998-10-26 2000-04-28 Univ Pasteur Utilisation du gdnf pour le traitement de la degenerescence retinienne
EP1033405A3 (en) * 1999-02-25 2001-08-01 Ceres Incorporated Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
EP1242443A4 (en) * 1999-12-23 2005-06-22 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
FR2823221B1 (fr) 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
WO2010029130A1 (en) 2008-09-10 2010-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuronal viability factor and use thereof

Also Published As

Publication number Publication date
IL199316A (en) 2011-01-31
US8114849B2 (en) 2012-02-14
CA2443345A1 (en) 2002-10-17
JP2005502319A (ja) 2005-01-27
ES2597835T3 (es) 2017-01-23
IL158013A0 (en) 2004-03-28
NO20034452D0 (no) 2003-10-03
US20120108523A1 (en) 2012-05-03
BRPI0208870B1 (pt) 2016-01-12
CZ20032706A3 (cs) 2003-12-17
FR2823221B1 (fr) 2004-04-02
US20040204350A1 (en) 2004-10-14
EP1379657B1 (en) 2016-08-17
AU2002312794B8 (en) 2006-01-12
PL213658B1 (pl) 2013-04-30
SK12232003A3 (sk) 2004-03-02
US20130287738A1 (en) 2013-10-31
PL364681A1 (en) 2004-12-13
US7795387B2 (en) 2010-09-14
CZ305800B6 (cs) 2016-03-23
HUP0303730A2 (en) 2006-02-28
US20080004231A1 (en) 2008-01-03
ZA200307403B (en) 2004-04-21
KR100913258B1 (ko) 2009-08-21
CA2443345C (en) 2012-12-04
RU2384586C2 (ru) 2010-03-20
US8071745B2 (en) 2011-12-06
RU2003130638A (ru) 2005-04-20
WO2002081513A2 (en) 2002-10-17
KR20030094317A (ko) 2003-12-11
US20090062188A1 (en) 2009-03-05
CN1529753B (zh) 2013-06-12
SK288465B6 (sk) 2017-06-02
BR0208870A (pt) 2004-04-27
US8394756B2 (en) 2013-03-12
JP2009232843A (ja) 2009-10-15
EP1379657A2 (en) 2004-01-14
JP4370428B2 (ja) 2009-11-25
NO331277B1 (no) 2011-11-14
BRPI0208870B8 (pt) 2021-05-25
CN1529753A (zh) 2004-09-15
JP4571695B2 (ja) 2010-10-27
NO20034452L (no) 2003-12-04
US8518695B2 (en) 2013-08-27
MXPA03009114A (es) 2004-11-22
IL158013A (en) 2010-12-30
FR2823221A1 (fr) 2002-10-11
US20120108657A1 (en) 2012-05-03
US8957043B2 (en) 2015-02-17
NZ528376A (en) 2005-09-30
AU2002312794B2 (en) 2005-12-01
WO2002081513A3 (en) 2003-05-01
HU226307B1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
ECSP024345A (es) Proteina asociada con enfermedad
WO2004075823A8 (fr) Derives de benzimidazole et d’imidazo-pyridine ayant une addinite pour les recepteurs des melanocortines et leur utilisation en tant que medicament
WO2005055945A3 (en) Mucoadhesive drug delivery devices and methods of making and using thereof
WO2010085100A2 (ko) 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
EP2982696A3 (en) Treatment of acute lymphoblastic leukemia
CL2011000867A1 (es) Formas cristalinas da, c y ii de (r)-5-[3-cloro-4-(2,3-dihidroxi-propoxi)- benz[z]ilideno]-2- ([z]- propilimino) -3-o- totil-tiazolidin-4-ona; composicion farmaceutica; y uso en el tratamiento o prevencion de rechazo de organos trasplantados, sindrome autoinmunitarios, asma, diabetes, cancer.
PA8477801A1 (es) (3s) tetrahidro-3-furanil (1s,2r)-3-[[4-aminofenil) sulfonil)] (isobutil) amino]-1-bencil-2-(fosfonooxi) propilcarbamato de calcio
NO20062767L (no) Immunoglobuliner
CY1112981T1 (el) Μεθοδος και συνθεση για την αγωγη της ρινιτιδας
CL2004000710A1 (es) Composicion antimicrobiana y antiparasitaria formada por un antibiotico derivado del cloranfenicol o tianfenicol, un endectocida y por lo menos un vehiculo aceptable, y su uso para tratar enfermedades respiratorias y parasitarias de los bovinos.
EP2862867A3 (en) Methods and compositions for the treatment of Marfan syndrome and associated disorders
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
NO20054180D0 (no) Behandling av bakterielle sykdommer i andedrettsorganene ved lokal tilforsel av fluorkinoloner
NO20054535L (no) Bifunksjonelle heterocykliske forbindelser og fremgangsmater for fremstilling og anvendelse av samme
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
WO2007076091A3 (en) Treatment of viral infections using a tissue factor inhibitor
BRPI0618370A2 (pt) formulação aerossol de medicamento, uso do mesmo e kit de inalação
WO2006019984A3 (en) Compositions, methods and kits for the diagnosis and treatment of sudden infant death syndrome
IL175237A0 (en) Pentafluorosulfanyl benzoylguanidines, method for their production, their use as medicaments or diagnostic agents and medicament containing the same
WO2006125818A3 (en) Oral pharmaceutical formulation for the prevention and/or the treatment of cardiovascular and inflammatory diseases
WO2008028888A3 (en) Use of cripto-1 or cripto-3 for the treatment of skeletal muscle wasting
WO2006090365A3 (en) Polysaccharide-oligoamine conjugates as anti-amyloid and anti-viral agents
NO20060229L (no) Gaboxadol for behandling av depresjon og andre affektive lidelser